Literature DB >> 16867042

Adverse side-effects to biological agents.

W J Pichler1.   

Abstract

Biological agents-like cytokines, monoclonal antibodies and fusion proteins are widely used in anti-inflammatory and tumour therapy. They are highly efficient in certain diseases, but can cause a great variety of adverse side-effects. Based on the peculiar features of biological agents a new classification of these adverse side-effects of biological agents is proposed - related but clearly distinct from the classification of side-effects observed with chemicals and drugs. This classification differentiates five distinct types, namely clinical reactions because of high cytokine levels (type alpha), hypersensitivity because of an immune reaction against the biological agent (beta), immune or cytokine imbalance syndromes (gamma), symptoms because of cross-reactivity (delta) and symptoms not directly affecting the immune system (epsilon). This classification could help to better deal with the clinical features of these side-effects, to identify possible individual and general risk factors and to direct research in this novel area of medicine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16867042     DOI: 10.1111/j.1398-9995.2006.01058.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  45 in total

1.  A cohort study exploring determinants of safety-related regulatory actions for biopharmaceuticals.

Authors:  Hans C Ebbers; Aukje K Mantel-Teeuwisse; Ellen H M Moors; Fakhredin A Sayed Tabatabaei; Huub Schellekens; Hubert G M Leufkens
Journal:  Drug Saf       Date:  2012-05-01       Impact factor: 5.606

2.  EIDOS: a mechanistic classification of adverse drug effects.

Authors:  Robin E Ferner; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2010-01-01       Impact factor: 5.606

3.  [Undesired cutaneous adverse drug reactions: What is new?].

Authors:  R Treudler; J C Simon
Journal:  Internist (Berl)       Date:  2012-08       Impact factor: 0.743

Review 4.  Reporting, Visualization, and Modeling of Immunogenicity Data to Assess Its Impact on Pharmacokinetics, Efficacy, and Safety of Monoclonal Antibodies.

Authors:  Chaitali Passey; Satyendra Suryawanshi; Kinjal Sanghavi; Manish Gupta
Journal:  AAPS J       Date:  2018-02-26       Impact factor: 4.009

5.  Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.

Authors:  Thijs J Giezen; Aukje K Mantel-Teeuwisse; Ronald H B Meyboom; Sabine M J M Straus; Hubert G M Leufkens; Toine C G Egberts
Journal:  Drug Saf       Date:  2010-10-01       Impact factor: 5.606

Review 6.  Adverse reactions to biologic agents and their medical management.

Authors:  Onur Boyman; Denis Comte; François Spertini
Journal:  Nat Rev Rheumatol       Date:  2014-08-12       Impact factor: 20.543

Review 7.  Kinase inhibitors and monoclonal antibodies in oncology: clinical implications.

Authors:  Helen Gharwan; Hunter Groninger
Journal:  Nat Rev Clin Oncol       Date:  2015-12-31       Impact factor: 66.675

8.  Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?

Authors:  Claudio Galarza; Diana Valencia; Gabriel J Tobón; Luis Zurita; Rubén D Mantilla; Ricardo Pineda-Tamayo; Adriana Rojas-Villarraga; Juan C Rueda; Juan-Manuel Anaya
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

Review 9.  [Dermatological symptoms in rheumatology].

Authors:  E Aberer
Journal:  Z Rheumatol       Date:  2008-09       Impact factor: 1.372

10.  How safe are the biologicals in treating asthma and rhinitis?

Authors:  Linda S Cox
Journal:  Allergy Asthma Clin Immunol       Date:  2009-10-22       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.